Chronic Cutaneous-Visceral Leishmaniasis: A Forgotten Differential Diagnosis

Main Article Content

R. Rivera-Dominguez
Y. Urias-Ramirez
E. Caballero-Leesama
E Rodriguez-Flores
J. Ramirez Garcia
A. Trujillo Cabrera
J. Mendoza Mendoza
E. Antonio-Calixto

Abstract

Leishmaniasis is a vector-borne disease. Three types of manifestations are recognized in the literature: Cutaneous, Mucocutaneous, and Visceral. The transmission and infection mechanism begins when the sandfly feeds on blood and regurgitates promastigotes into the skin, which are phagocytosed by macrophages. The diagnosis is based on clinical features and laboratory tests, such as direct parasitological examination, to increase diagnostic accuracy. Regarding the first case of Visceral Leishmaniasis in the state of Guerrero. An 18-year-old man with unspecified dermatitis since the age of 8, which began with an unquantified, intermittent fever, predominantly in the evening. On the fourth day, the patient presented edema in the auricles, itching, erythema, and increased local temperature that evolved into a papule and blister, with the formation of an indurated scab that, when detached, leaves an ulcer. This invades subcutaneous cellular tissue and disappears after 6 weeks, leaving an atrophic scar. This scar has occurred at least 6 times a year for 9 years, alternating between the auricles, elbows, and ankles. The patient therefore came for medical evaluation with an ulcer on the inner side and upper third of the left leg with an increase in diameter, edema, and a necrotic ulcer with purulent and foul-smelling discharge. A wound smear was requested, which was stained with Giemsa and found Leishmania spp. PCR with specific oligonucleotides: Mexican visceral Leishmania. After confirming the diagnosis of the disseminated mucocutaneous variant, it was decided to initiate systemic and local intralesional treatment with systemic antimonial. During follow-up, the patient observed scleroatrophic healing of previously ulcerated lesions, with no signs of infection or new lesions. It is important to understand leishmaniasis as a differential diagnosis for ulcerated lesions of variable distribution with a short or chronic course, and to perform the necessary studies to achieve appropriate treatment and improve the patient's prognosis.

Article Details

How to Cite
Rivera-Dominguez, R., Y. Urias-Ramirez, E. Caballero-Leesama, E Rodriguez-Flores, J. Ramirez Garcia, A. Trujillo Cabrera, J. Mendoza Mendoza, and E. Antonio-Calixto. 2025. “Chronic Cutaneous-Visceral Leishmaniasis: A Forgotten Differential Diagnosis”. International Journal of Medical Science and Clinical Research Studies 5 (10):1661-64. https://doi.org/10.47191/ijmscrs/v5-i10-03.
Section
Articles

References

I. Gurel MS, Tekin B, Uzun S. Cutaneous leishmaniasis: A great imitator. Clin Dermatol. 2020;38(2):140–51.

II. National Center for Disease Prevention and Control (CENAPRECE). Guidelines for the Medical Care of Leishmaniasis in Mexico [Internet]. Mexico: Ministry of Health; 2022.

III. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet [Internet]. 2018;392(10151):951–70.

IV. de Vries HJC, Schallig HD. Cutaneous leishmaniasis: A 2022 updated narrative review into diagnosis and management developments. Am J Clin Dermatol [Internet]. 2022;23(6):823–40.

V. Goto H, Lindoso JAL. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther [Internet]. 2010;8(4):419–33.

VI. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev [Internet]. 2006;19(1):111–26.

VII. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and treatment of leishmaniasis: Clinical practice guidelines by the infectious diseases society of America (IDSA) and the American society of tropical medicine and hygiene (ASTMH). Clin Infect Dis [Internet]. 2016;63(12):1539–57.

VIII. Graziano T, Ferdock AJ, Rossi CM, Schultz KL. A case of cutaneous leishmaniasis with mucosal involvement in the northern United States. J Emerg Med [Internet]. 2024;66(6):e690–3.

IX. Taxy JB, Goldin HM, Dickie S, Cibull T. Cutaneous leishmaniasis: Contribution of routine histopathology in unexpected encounters. Am J Surg Pathol [Internet]. 2019;43(2):195–200.

X. Neitzke-Abreu HC, Venazzi MS, Bernal MVZ, Reinhold-Castro KR, Vagetti F, Mota CA, et al. Leishmania (Viannia) DNA detection: accuracy of polymerase chain reaction for the diagnosis of cutaneous leishmaniasis. PLoS One [Internet]. 2013;8(7):e62473.

XI. Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opinion Pharmacother [Internet]. 2019;20(10):1251–65.

XII. Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, et al. Recent development of treatments for visceral leishmaniasis: Successes, challenges, and prospects. Clin Microbiol Rev [Internet]. 2018;31(4).

XIII. Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis. J Am Acad Dermatol [Internet]. 2015;73(6):911–26.